There are 2789 resources available
1226P - Efficacy and safety of Anti-EGFR TKIs combined with bevacizumab or ramucirumab in the first-line treatment of non-small cell lung cancer: Meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: ePoster Display
1229P - Co-mutation of DNA damage repair (DDR) genes influence the efficiency of EGFR-TKIs in NSCLC patients harboring EGFR activating mutations
Presenter: Linlin Zhang
Session: ePoster Display
1230P - Elderly patients treated with afatinib in clinical practice: Final results of the GIDEON study in EGFR mutated NSCLC in Germany
Presenter: Wolfgang M Brueckl
Session: ePoster Display
1231P - Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
Presenter: James Chih-Hsin Yang
Session: ePoster Display
1152P - Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
Presenter: M. Kuruvilla
Session: ePoster Display
1153P - Classification of multifocal lung adenocarcinomas subtypes using next-generation sequencing in pN0M0 lung adenocarcinomas
Presenter: Xin Zhang
Session: ePoster Display
1154P - Circulating tumor DNA analysis integrating tumor clonality detects minimal residual disease in resectable non-small cell lung cancer
Presenter: Rong Yin
Session: ePoster Display
1155P - Univariable and multivariable two-sample Mendelian randomization investigating the effects of leisure sedentary behavior on the risk of lung cancer
Presenter: Haoxin Peng
Session: ePoster Display